23 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250422468615/en/CORCEPT-TO-PRESENT-LATE-BREAKING-DATA-FROM-PIVOTAL-PHASE-3-ROSELLA-TRIAL-OF-RELACORILANT-IN-PLATINUM-RESISTANT-OVARIAN-CANCER-AT-ASCO-2025
03 Mar 2025
// BUSINESSWIRE
30 Dec 2024
// BUSINESSWIRE
16 Dec 2024
// BUSINESSWIRE
03 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/03/2892174/0/en/Corcept-Therapeutics-Announces-Presentations-of-Results-of-Pivotal-Phase-3-GRACE-Trial-Evaluating-Relacorilant-in-Patients-with-Hypercortisolism-Cushing-s-Syndrome.html
28 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/28/2888977/0/en/Corcept-Announces-Primary-Endpoint-Met-in-Pivotal-Phase-3-GRACE-Trial-of-Relacorilant-in-Patients-With-Hypercortisolism-Cushing-s-Syndrome.html